Under the new rules, high-potency narcotics for opioid use disorder will be distributed by licensed AHS clinics and patients will take them there, witnessed by a health professional.
A U.S. federally funded systematic evidence review of 3,000 studies (25 of which had scientifically valid evidence) found that just three products showed evidence providing pain relief.